on-Invasive Magnetic Resonance Imaging Biomarkers to Evaluate Histology Proven Kidney Fibrosis in Chronic Kidney Disease

Not Applicable

Recruiting

• Conditions: Chronic Kidney Disease; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12622000855729
• Lead Sponsor: Professor Martin Ugander

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-17
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

All participants (CKD and healthy volunteers)
-Willing and able to provide informed consent

Healthy volunteers:
- No known medical conditions

CKD participants:
- Baseline eGFR > 15ml/min/1.73m2
- Clinical indication to undergo kidney biopsy (including native and transplanted kidney)

Exclusion Criteria

Contraindication to MRI
Contraindication to Gadolinium-based contrast agents
Dialysis dependent CKD
Pregnant or breastfeeding females

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of kidney fibrosis quantified by histology in individuals with CKD[ Kidney biopsy to be performed within 1 month prior to MRI]

Secondary Outcome Measures

Name	Time	Method
eGFR (ml/min/1.73m2) levels in individuals with chronic kidney disease calculated by serum (blood) creatinine.[ Blood test to be performed within 2 weeks of MRI];Albuminuria (mg/mmol) levels in individuals with chronic kidney disease assessed by urinalysis.[ Urinalysis to be performed within 4 weeks of MRI]